GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...
He’ll examine Shingrix's real-world effectiveness in preventing HZ infection while estimating the vaccine’s effectiveness in preventing incident dementia and other adverse cognitive and neurological ...
-- Positive data from 876-patient head-to-head trial versus Shingrix ® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity ...
Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
30, missing market expectations of 238 million pounds, while sales of shingles vaccine, Shingrix, fell 7% to 739 million pounds, also below estimates in a company compiled consensus. Walmsley told ...
Amezosvatein and Shingrix are adjuvanted recombinant protein subunit vaccines targeting glycoprotein E (gE), the most abundant glycoprotein expressed on the surface of the varicella zoster virus ...
Amezosvatein and Shingrix are adjuvanted recombinant protein subunit vaccines targeting glycoprotein E (gE), the most abundant glycoprotein expressed on the surface of the varicella zoster virus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback